Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew G Chapple

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
JAMA Network Open|March 9, 2022
Use of Machine Learning Approaches and Statistical Techniques to Adjust for Nonadherence in Randomized Clinical TrialsAndrew G Chapple
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|September 26, 2022
Clinical Advantages of Immediate Posterior Implants With Custom Healing Abutments: Up to 8-Year Follow-Up of 115 CasesRichard Akin, Andrew G Chapple
Pharmaceutical Statistics|August 17, 2018
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combinationAndrew G Chapple, Peter F Thall
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F Thall
Biometrics|June 28, 2019
Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"Andrew G Chapple, Peter F Thall
Contemporary Clinical Trials|August 22, 2020
Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteriaAndrew G Chapple, Peter F Thall
Pharmaceutical Statistics|May 13, 2022
Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trialsAlana McGovern, Andrew G Chapple, Clement Ma
Statistics in Medicine|February 23, 2020
A novel Bayesian continuous piecewise linear log-hazard model, with estimation and inference via reversible jump Markov chain Monte CarloAndrew G Chapple, Taylor Peak, Ashok Hemal
Statistics in Medicine|April 16, 2022
Subgroup-specific dose finding for phase I-II trials using Bayesian clusteringAlexandra Curtis, Brian Smith, Andrew G Chapple
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|June 25, 2021
Is Screw-Fracture Proximity or Residual Fracture Displacement Correlated to Outcomes After Open Reduction and Internal Fixation of Mandibular Angle Fractures?Michael Certa, Andrew G Chapple, Brian J Christensen
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
JAMA Network Open|March 9, 2022
Use of Machine Learning Approaches and Statistical Techniques to Adjust for Nonadherence in Randomized Clinical TrialsAndrew G Chapple
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|September 26, 2022
Clinical Advantages of Immediate Posterior Implants With Custom Healing Abutments: Up to 8-Year Follow-Up of 115 CasesRichard Akin, Andrew G Chapple
Pharmaceutical Statistics|August 17, 2018
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combinationAndrew G Chapple, Peter F Thall
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F Thall
Biometrics|June 28, 2019
Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"Andrew G Chapple, Peter F Thall
Contemporary Clinical Trials|August 22, 2020
Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteriaAndrew G Chapple, Peter F Thall
Pharmaceutical Statistics|May 13, 2022
Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trialsAlana McGovern, Andrew G Chapple, Clement Ma
Statistics in Medicine|February 23, 2020
A novel Bayesian continuous piecewise linear log-hazard model, with estimation and inference via reversible jump Markov chain Monte CarloAndrew G Chapple, Taylor Peak, Ashok Hemal
Statistics in Medicine|April 16, 2022
Subgroup-specific dose finding for phase I-II trials using Bayesian clusteringAlexandra Curtis, Brian Smith, Andrew G Chapple
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|June 25, 2021
Is Screw-Fracture Proximity or Residual Fracture Displacement Correlated to Outcomes After Open Reduction and Internal Fixation of Mandibular Angle Fractures?Michael Certa, Andrew G Chapple, Brian J Christensen
Pageof 7